RenovoRx

04/17/2026

Thank you Nasdaq for featuring RenovoRx and for recognizing our inclusion in Fast Company's 2026 World’s Most Innovative Medical Device Companies list! Our team is committed to transforming the lives of cancer patients through innovative targeted drug-delivery via our TAMP™ therapy platform. Learn about our work: https://bit.ly/49zQls2

04/14/2026

Congratulations to Dr. Mustafa Al-Roubaie and a team of experts at Moffitt Cancer Center on their clinical data abstract presented yesterday at the ! The data shows the TAMP therapy platform to be a promising approach for local delivery of gemcitabine with reduced systemic toxicity in patients diagnosed with . Further, metabolic imaging, used to evaluate therapeutic outcome following treatment with TAMP, shows a notable reduction in tumor activity suggesting a potential treatment response. For details: https://bit.ly/4cqwsWs

04/08/2026

RenovoRx’s first notice of allowance for Japanese patent strengthens RenovoRx’s global intellectual property, supports the Company’s approach to targeted drug-delivery, and expands protection for its therapy platform in the strategically important Japanese market. Read more about RenovoRx's strong and growing global IP portfolio: https://bit.ly/4sYGxB9

04/08/2026

RenovoRx announced that the Japan Patent Office has issued a Notice of Allowance for the Company’s first Japanese patent application (JP 2024-559262) titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum.” The patent covers the RenovoCath® device for targeted, local drug-delivery via the vasa vasorum. RenovoRx currently holds a strong and growing global intellectual property portfolio with 19 issued or allowed patents and 14 pending patents supporting the commercialization of RenovoCath. Learn more: https://bit.ly/4sYGxB9

04/06/2026

In an interview with Pharma Sessions, our CEO, Shaun Bagai, explains how listening to physician feedback shaped the commercialization strategy for RenovoCath® as a stand-alone, targeted drug-delivery device. He also discusses RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial. .

Listen here: https://bit.ly/4mgkpQ3

After stepping away from the traditional path to medical school, Shaun Bagai pursued a different way to impact patient care: building technologies that chang...

04/01/2026

RenovoRx is pleased to announce that it has been named on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026. This annual recognition highlights organizations that are shaping industry and culture through their innovations, learn more: https://bit.ly/3QeP308

03/31/2026

ICYMI: We announced financial results and business updates for FY & Q4 2025, highlighting our first full year of RenovoCath® commercialization, driven by the growing adoption by new and existing active commercial cancer centers. Learn more: https://bit.ly/4m6dsRM

03/30/2026

2025 marked a key year for RenovoRx as it was the first full year of RenovoCath commercialization, reflecting strong initial physician adoption and demand in a handful of active commercial cancer centers. With $13 million on hand, the Company has the funding, business plan, leadership, and infrastructure to drive growth and shareholder value. Management will host a conference call today, March 30th, at 4:30 PM ET. For details: https://bit.ly/4m6dsRM

03/30/2026

We’re honored to be named one of the 2026 World’s Most Innovative Medical Device Companies by Fast Company.

This recognition is a tribute to the RenovoRx team's commitment to transforming the lives of cancer patients by providing innovative solutions for targeted delivery of therapeutic agents in difficult-to-treat tumors, like .

Innovation in cancer care cannot wait!

https://bit.ly/4bHgV5J

03/30/2026

Reminder – we are hosting our fourth quarter and full year 2025 financial results and business highlights conference call today, March 30th at 4:30 p.m. ET. For webcast details: https://bit.ly/47YQg1I

03/26/2026

Leesa Gentry, Chief Clinical Officer of RenovoRx, highlights the Company’s key milestone as the Phase III TIGeR-PaC clinical trial nears enrollment completion. Select TIGeR-PaC cancer centers are now using RenovoCath® as a standalone device for drug-delivery in oncology management. Learn more: https://bit.ly/41tpTxc

03/26/2026

RenovoRx today announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion in the first half of 2026, with final data expected in 2027. For details: https://bit.ly/41tpTxc